The stock has a 36-month beta value of 1.02. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BNTC is 2.42M, and at present, short sellers hold a 0.45% of that float. On April 18, 2024, the average trading volume of BNTC was 18.72K shares.
BNTC) stock’s latest price update
Benitec Biopharma Inc (NASDAQ: BNTC)’s stock price has plunge by 12.00relation to previous closing price of 4.80. Nevertheless, the company has seen a -13.71% plunge in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-05-08 that HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A.
BNTC’s Market Performance
Benitec Biopharma Inc (BNTC) has seen a -13.71% fall in stock performance for the week, with a 6.04% gain in the past month and a 67.27% surge in the past quarter. The volatility ratio for the week is 9.82%, and the volatility levels for the past 30 days are at 7.35% for BNTC. The simple moving average for the past 20 days is 0.89% for BNTC’s stock, with a 51.16% simple moving average for the past 200 days.
Analysts’ Opinion of BNTC
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see BNTC reach a price target of $14. The rating they have provided for BNTC stocks is “Buy” according to the report published on April 20th, 2020.
BNTC Trading at 16.51% from the 50-Day Moving Average
After a stumble in the market that brought BNTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.33% of loss for the given period.
Volatility was left at 7.35%, however, over the last 30 days, the volatility rate increased by 9.82%, as shares surge +0.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +80.60% upper at present.
During the last 5 trading sessions, BNTC fell by -13.32%, which changed the moving average for the period of 200-days by +34.03% in comparison to the 20-day moving average, which settled at $5.33. In addition, Benitec Biopharma Inc saw 66.44% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for BNTC
Current profitability levels for the company are sitting at:
- -355.61 for the present operating margin
- 0.82 for the gross margin
The net margin for Benitec Biopharma Inc stands at -358.57. The total capital return value is set at -1.39. Equity return is now at value -178.30, with -131.16 for asset returns.
Based on Benitec Biopharma Inc (BNTC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -42.71. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -1446.13.
Currently, EBITDA for the company is -18.73 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of -73.77. The receivables turnover for the company is 1.15for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
To sum up, Benitec Biopharma Inc (BNTC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
